Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Ossium Health, Inc.
M.D. Anderson Cancer Center
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Instituto Nacional de Cancer, Brazil
Assiut University
Roswell Park Cancer Institute
Atara Biotherapeutics
Columbia University
Spectrum Pharmaceuticals, Inc
Gamida Cell ltd
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Ciusss de L'Est de l'Île de Montréal
University of Michigan Rogel Cancer Center
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
University of Washington
Singapore General Hospital
National Cancer Institute (NCI)
Polyphor Ltd.
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
University of Erlangen-Nürnberg Medical School
Targazyme, Inc.
National Cancer Institute (NCI)
University of Kentucky
National Cancer Institute (NCI)
Asan Medical Center
Washington University School of Medicine
Baylor College of Medicine
Northwestern University
Northwestern University
UNC Lineberger Comprehensive Cancer Center
Accenture
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center